JPWO2020047328A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020047328A5
JPWO2020047328A5 JP2021511588A JP2021511588A JPWO2020047328A5 JP WO2020047328 A5 JPWO2020047328 A5 JP WO2020047328A5 JP 2021511588 A JP2021511588 A JP 2021511588A JP 2021511588 A JP2021511588 A JP 2021511588A JP WO2020047328 A5 JPWO2020047328 A5 JP WO2020047328A5
Authority
JP
Japan
Prior art keywords
domain
cancer
binding
pharmaceutical composition
extracellular domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021511588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512541A (ja
JP2022512541A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048923 external-priority patent/WO2020047328A1/en
Publication of JP2022512541A publication Critical patent/JP2022512541A/ja
Publication of JP2022512541A5 publication Critical patent/JP2022512541A5/ja
Publication of JPWO2020047328A5 publication Critical patent/JPWO2020047328A5/ja
Pending legal-status Critical Current

Links

JP2021511588A 2018-08-29 2019-08-29 Pd-1系キメラタンパク質を含む併用療法 Pending JP2022512541A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862724600P 2018-08-29 2018-08-29
US62/724,600 2018-08-29
US201862734951P 2018-09-21 2018-09-21
US62/734,951 2018-09-21
US201962793235P 2019-01-16 2019-01-16
US62/793,235 2019-01-16
US201962832830P 2019-04-11 2019-04-11
US62/832,830 2019-04-11
US201962890217P 2019-08-22 2019-08-22
US62/890,217 2019-08-22
PCT/US2019/048923 WO2020047328A1 (en) 2018-08-29 2019-08-29 Combination therapies comprising pd-1-based chimeric proteins

Publications (3)

Publication Number Publication Date
JP2022512541A JP2022512541A (ja) 2022-02-07
JP2022512541A5 JP2022512541A5 (https=) 2022-09-06
JPWO2020047328A5 true JPWO2020047328A5 (https=) 2022-09-06

Family

ID=69644684

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511588A Pending JP2022512541A (ja) 2018-08-29 2019-08-29 Pd-1系キメラタンパク質を含む併用療法
JP2021511586A Ceased JP2022511286A (ja) 2018-08-29 2019-08-29 Sirpアルファ系キメラタンパク質を含む併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021511586A Ceased JP2022511286A (ja) 2018-08-29 2019-08-29 Sirpアルファ系キメラタンパク質を含む併用療法

Country Status (9)

Country Link
US (2) US20210379153A1 (https=)
EP (2) EP3844176A4 (https=)
JP (2) JP2022512541A (https=)
CN (2) CN112839952A (https=)
AU (2) AU2019327494A1 (https=)
CA (2) CA3109354A1 (https=)
IL (2) IL281095A (https=)
MX (2) MX2021002294A (https=)
WO (2) WO2020047319A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047319A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising sirp alpha-based chimeric proteins
WO2021195472A1 (en) * 2020-03-26 2021-09-30 Aetio Biotherapy, Inc. Bi-specific fusion proteins for depletion of regulatory t cells
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
MX2023003142A (es) * 2020-09-17 2023-05-17 Shattuck Labs Inc Dosificacion clinica de proteina quimerica sirp1a.
AU2021378152A1 (en) * 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
EP4274852A4 (en) * 2021-01-11 2025-02-26 Eutilex Co., Ltd. BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
EP4301470A4 (en) * 2021-03-05 2025-01-22 Shattuck Labs, Inc. COMBINATION THERAPIES WITH SIRP-ALPHA-BASED CHIMERIC PROTEINS
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体,その使用方法および遺伝子治療のための分子スイッチ
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
NZ592420A (en) * 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
ES2914814T3 (es) * 2012-12-17 2022-06-16 Pf Argentum Ip Holdings Llc Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
EA038981B1 (ru) * 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Вирусы болезни ньюкасла и их применение
KR20160093012A (ko) * 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
BR112017016681A2 (pt) * 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
RU2766200C1 (ru) * 2015-10-01 2022-02-09 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
CA3047394A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
LT3565579T (lt) * 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
MX2019009812A (es) 2017-02-27 2019-10-14 Shattuck Labs Inc Proteinas quimericas basadas en tigit y light.
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
WO2020047319A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising sirp alpha-based chimeric proteins

Similar Documents

Publication Publication Date Title
JP2022512541A5 (https=)
JP2022511286A5 (https=)
JP7102670B2 (ja) 抗pd‐l1抗体とil‐7との融合
JP7198083B2 (ja) Cd47遮断及び免疫同時刺激アゴニストを用いた標的細胞の枯渇亢進
JP2020530298A5 (https=)
JPWO2021142002A5 (https=)
US12391764B2 (en) Anti-CD30 and anti-CD3 bispecific antibodies and methods of immunotherapy for CD30+ malignancies
JP2022179623A (ja) 抗ox40抗体及びその用途
US20220411512A1 (en) Combination treatment for cancer
JP7362614B2 (ja) 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質
EP4556486A1 (en) Trispecific antibody and use thereof
JP2024501809A (ja) Ceacam5およびcd47に対する二重特異性抗体
TW202313682A (zh) 抗icos抗體之用途
WO2022218383A1 (zh) 抗体在抗肿瘤治疗中的用途
JPWO2020047328A5 (https=)
JP2022512539A5 (https=)
WO2024078479A1 (zh) 一种异源二聚体融合蛋白及其应用
TW202131950A (zh) 依序抗cd19療法
JPWO2020047319A5 (https=)
JPWO2020047325A5 (https=)
CN118221826A (zh) 一种结合人cd33和cd3的双特异性抗体
LT7127B (lt) Į bcma nukreipta car-t ląstelių terapija dauginei mielomai gydyti
JP2022503621A5 (https=)
JPWO2020047322A5 (https=)
RU2021108091A (ru) Комбинированные виды терапии